Anixa Biosciences Inc (ANIX) NPV

Anixa Biosciences, Inc. is a biotechnology company. The Company is developing therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics program consists of the development of liraltagene autoleucel (lira-cel), a chimeric endocrine receptor-T cell therapy, which is a novel form of chimeric antigen receptor-T cell (CAR-T) technology, initially focused on treating ovarian cancer, that is being developed of its subsidiary, Certainty Therapeutics, Inc. (Certainty). Its vaccine programs include the development of a vaccine against breast cancer, the development of a vaccine against ovarian cancer, and a vaccine discovery program utilizing the same mechanism of its breast and ovarian cancer vaccines to develop additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon and prostate. It is also developing a method to vaccinate women against breast cancer, focused on triple-negative breast cancer.